SecBot SecBot
SECBOTREPLAY Home › Report › VERA

VERA · Vera Therapeutics announced the transition of Chief Regulatory Officer…

Vera Therapeutics, Inc. · 8-K filed Jul 9, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Jul 9, 2026 at 08:00 ET

Vera Therapeutics announced the transition of Chief Regulatory Officer William Turner to Special Advisor for Regulatory Affairs, effective August 3, 2026, with Nancy Bowman, M.D., Ph.D., succeeding him as CRO. This is a routine, orderly leadership change with a named successor, carrying no material operational or financial implications.

  • William Turner steps down as Chief Regulatory Officer, transitions to Special Advisor for Regulatory Affairs effective August 3, 2026.
  • Nancy Bowman, M.D., Ph.D., appointed as the new Chief Regulatory Officer, effective August 3, 2026.
  • Orderly succession with both outgoing and incoming roles clearly defined.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access